Brv 50 mg (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
309 | Progressive myoclonus epilepsy | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00368251 (ClinicalTrials.gov) | November 2006 | 23/8/2006 | Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (= 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease | Unverricht-Lundborg Disease | Other: Placebo;Drug: BRV 2.5 mg;Drug: BRV 25 mg;Drug: BRV 50 mg | UCB Pharma | NULL | Completed | 16 Years | N/A | All | 56 | Phase 3 | United States;Canada;Finland;France;Israel;Russian Federation;Serbia;Tunisia;Former Serbia and Montenegro |